Suppr超能文献

柔性玉米醇溶蛋白纳米颗粒提高大麻二酚的口服生物利用度及药代动力学研究

Enhanced oral bioavailability of cannabidiol by flexible zein nanoparticles: and pharmacokinetic studies.

作者信息

Nie YingLan, Kong Yan, Peng Juan, Sun Jian, Fan Bin

机构信息

Beijing Key Laboratory of Basic Research on Traditional Chinese Medicine to Prevent and Control Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.

出版信息

Front Nutr. 2024 Jul 17;11:1431620. doi: 10.3389/fnut.2024.1431620. eCollection 2024.

Abstract

INTRODUCTION

Cannabidiol (CBD) has a variety of pharmacological effects including antiepileptic, antispasmodic, anxiolytic and anti-inflammatory among other pharmacological effects. However, since CBD is a terpene-phenolic compound, its clinical application is limited by its poor water solubility, low stability, and low bioavailability.

METHODS

In this study, we used several strategies to address the above problems. Hydrochloric acid was used to modify zein to improve the molecular flexibility. Flexible zein nanoparticles (FZP-CBD) loaded with CBD was prepared to improve the stability and bioavailability of CBD. The parameters were evaluated in terms of morphology, particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE%), loading capacity (LC%), and storage stability. Simulated gastrointestinal fluid release experiment and bioavailability assay were applied in the evaluation.

RESULTS

The simulated gastrointestinal fluid experiment showed that the release rates of FZP-CBD and natural zein nanoparticles (NZP-CBD) loaded with CBD were 3.57% and 89.88%, respectively, after digestion with gastric fluid for 2 h, 92.12% and 92.56%, respectively, after intestinal fluid digestion for 2 h. Compared with NZP-CBD, the of FZP-CBD at 3 different doses of CBD was increased by 1.7, 1.3 and 1.5 times respectively, and AUC was increased by 1.4, 1.1 and 1.7 times respectively, bioavailability (F) was increased by 135.9%, 114.9%, 169.6% respectively.

DISCUSSION

The experimental results showed that FZP-CBD could protect most of the CBD from being released in the stomach, and then control its release in the intestines, promote the absorption of CBD in the small intestine, and increase the bioavailability of CBD. Therefore, FZP-CBD could improve the utilization value of CBD and provide a new idea for the application of CBD in medicine and pharmacy.

摘要

引言

大麻二酚(CBD)具有多种药理作用,包括抗癫痫、解痉、抗焦虑和抗炎等其他药理作用。然而,由于CBD是一种萜烯酚类化合物,其临床应用受到水溶性差、稳定性低和生物利用度低的限制。

方法

在本研究中,我们采用了几种策略来解决上述问题。使用盐酸对玉米醇溶蛋白进行改性以提高分子柔韧性。制备负载CBD的柔性玉米醇溶蛋白纳米颗粒(FZP-CBD)以提高CBD的稳定性和生物利用度。从形态、粒径(PS)、多分散指数(PDI)、zeta电位(ZP)、包封率(EE%)、载药量(LC%)和储存稳定性等方面对参数进行评估。在评估中应用了模拟胃肠液释放实验和生物利用度测定。

结果

模拟胃肠液实验表明,负载CBD的FZP-CBD和天然玉米醇溶蛋白纳米颗粒(NZP-CBD)在胃液中消化2小时后的释放率分别为3.57%和89.88%,在肠液中消化2小时后的释放率分别为92.12%和92.56%。与NZP-CBD相比,FZP-CBD在3种不同剂量的CBD下的 分别提高了1.7、1.3和1.5倍,AUC分别提高了1.4、1.1和1.7倍,生物利用度(F)分别提高了135.9%、114.9%、169.6%。

讨论

实验结果表明,FZP-CBD可以保护大部分CBD不在胃中释放,然后控制其在肠道中的释放,促进CBD在小肠中的吸收,并提高CBD的生物利用度。因此,FZP-CBD可以提高CBD的利用价值,为CBD在医药和药学中的应用提供新思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d1a/11289775/c15f9b1a4811/fnut-11-1431620-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验